An Active Mechanism for Completion of the Final Stage of Protein Degradation in the Liver, Lysosomal Transport of Dipeptides*

(Received for publication, October 25, 1996, and in revised form, February 26, 1997)

Manikkavasagar Thamotharan , Yolanda B. Lombardo , Shahab Zare Bawani and Siamak A. Adibi Dagger

From the Clinical Nutrition Research Unit, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES


ABSTRACT

Accumulation of products of proteolysis (e.g. dipeptides) in lysosomes may have pathological consequences. In the present experiment we have investigated the existence of a dipeptide transporter in a membrane preparation of liver lysosomes using Gly-3H-Gln as the probe. The results showed that (a) there was transport of Gly-Gln into an osmotically reactive space inside the lysosomal membrane vesicles; (b) transport was stimulated by acidification (pH 5.0) of the external medium; (c) there was a coupling between transport of protons and Gly-Gln with a stoichiometry of 1:1; (d) the presence of both acidic pH and membrane potential was necessary for uphill transport of Gly-Gln; (e) a single transporter with a Km of 4.67 mM mediated the uptake of Gly-Gln; and (f) Gly-Gln uptake was inhibited by dipeptides and tripeptides but not by amino acids. The results suggest the presence of a low affinity proton-coupled oligopeptide transporter in the liver lysosomal membrane which mediates transfer of dipeptides from a region of low dipeptidase activity (intralysosome) to a region of high dipeptidase activity (cytosol). In this manner, the transporter provides an active mechanism for completion of the final stage of protein degradation.


INTRODUCTION

Lysosomes are major sites for protein degradation in the liver. Amino acids and dipeptides are the final products of proteolysis within this organelle (1, 2). These products must be exported into the cytosol if lysosomes are to retain their biological integrity. Failure to export may result in pathological consequences. This is evidenced by the genetic defect in the export of cystine, which results in accumulation of a high concentration of this amino acid in the lysosomes causing cystinosis. Cystinosis is a progressive systemic disease with many pathological expressions (3).

Although as yet no genetic disease of dipeptide accumulation in lysosomes has been described, there is evidence that such an accumulation would also have pathological effects. This is evidenced by the osmotic protection experiments which determine the rates of release of lysosomal enzymes. Lloyd (4) showed that incubation of lysosomes isolated from rat liver with 0.25 M solutions of dipeptides or their constituent amino acids increased the release of their enzyme contents. Furthermore, the release was greater with dipeptides than with their constituent amino acids. He suggested that amino acids and dipeptides enter the lysosomes, and the entry is more efficient for dipeptides than for amino acids. Recently, Bird and Lloyd (5) found that the rate of enzyme release was greater with dipeptides containing L-isomers than D-analogs, suggesting a stereospecificity in lysosomal permeation of dipeptides. However, as reviewed by Forster and Lloyd (6), the osmotic protection technique does not allow any conclusion regarding the mechanism which a solute uses for entry into the lysosomes. For example, the greater rate of enzyme release by dipeptides containing L- rather than D-amino acids could be explained by the hydrolysis of dipeptides within the lysosomes which is stereospecific (7). This is consistent with a more recent study of Bird and Lloyd (8) who found a positive correlation between ability of dipeptides to disrupt lysosomes and their susceptibility to hydrolysis by lysosomal enzymes.

To determine whether the liver lysosomal membrane indeed possesses a dipeptide transporter, in the present experiments we have used a membrane vesicle uptake technique which has been validated for the studies of solute transport by the liver lysosomes. Jonas and Jobe (9) showed that properties of rat liver lysosomal membrane, like the proton-pumping ATPase activity, are preserved in vesicle preparations. For the present experiment we used labeled glycylglutamine (Gly-Gln) as the probe because we have previously validated the use of this dipeptide for characterization of oligopeptide transport in membrane vesicles prepared from kidney and intestine (10, 11).


EXPERIMENTAL PROCEDURES

Materials

Adult male Harlan Sprague Dawley rats with body weights of 250-300 g were purchased from Zivic-Miller. Custom synthesized [glutamine-3,4-3H]glycylglutamine (49 Ci/mmol) was obtained from DuPont NEN. Amino acids, oligopeptides, carbonyl cyanide m-chlorophenylhydrazone (CCCP),1 and acridine orange dye were purchased from Sigma. Filters (type HAWP, 0.45 µm pore size) were purchased from Millipore Corp., Bedford, MA.

Preparation of Lysosomal Membrane Vesicles

Rats were killed and their livers were removed for preparation of lysosomal membrane vesicles (LMV). Vesicles were prepared as described by Symons and Jonas (12). Briefly, livers were homogenized in buffer 1 (250 mM sucrose, 20 mM Hepes, 1 mM EDTA, pH 7.0, with Tris base) containing 1 µg/ml pepstatin and 2 µg/ml leupeptin, using a Dounce homogenizer. The liver homogenate was suspended at an average protein concentration of 35 mg/ml in buffer 1 and centrifuged for 20 min at 750 × g. The nuclear pellet was discarded and the centrifugation was repeated. The resulting supernatant was centrifuged for 10 min at 20,000 × g, and the pellet was resuspended in buffer 2 (250 mM sucrose, 20 mM Hepes, pH 7.0, with Tris base) and recentrifuged for 10 min at 20,000 × g. The final pellet was suspended in 9 ml of buffer 2 and mixed with 11 ml of isotonic Percoll (1 ml of 2.5 M sucrose, 200 mM Hepes/Tris, pH 7.0, mixed with 9 ml of Percoll). The resulting Percoll mixture was centrifuged for 90 min at 40,000 × g. The dense brownish lysosomal band near the bottom of the gradient was removed and diluted with buffer 2 and centrifuged for 10 min at 20,000 × g. The resulting pellet containing lysosomes was incubated in freshly prepared solution containing 5 mM methionine methyl ester, 2 mg/ml bovine serum albumin, 2 mM magnesium chloride, 2 µg/ml leupeptin, and 1 µg/ml pepstatin for 15-20 min at 37 °C. Following this treatment, an equal volume of ice-cold isotonic Percoll was added. The mixture was centrifuged for 30 min at 35,000 × g. A dark brown band located at the top of this dense gradient containing purified LMV was removed and diluted in buffer 2 and centrifuged at 20,000 × g. The purified LMV pellet was resuspended in transport buffer sufficient to provide 3-5 mg/ml protein content. All of the above procedures were done at 4 °C. Protein content of the preparation was assessed with the Bio-Rad protein assay. The purity of the LMV preparation was investigated by determining enrichment of organelle and membrane marker enzymes. The activities of beta -hexosaminidase, 5'-nucleotidase, cytochrome c oxidase, and beta -glucosidase in liver homogenate and vesicle suspension were measured by the methods described previously (13-15).

Gly-Gln Uptake by LMV

Uptake studies by LMV were performed at 23 °C using a rapid filtration technique as described previously (10). Gly-Gln uptake was initiated by mixing 20 µl of membrane suspension (preloaded with 100 mM KCl, 100 mM sucrose, 20 mM Hepes/Tris at pH 7.0) preincubated with 50 µM valinomycin and incubated with 180 µl of transport buffer containing 0.1 mM Gly-3H-Gln. Composition of the transport buffer varied with different experiments and is described in the figure legends. Incubation of vesicles was terminated by injecting 20 µl of vesicle mixture into 2 ml of ice-cold stop solution (same composition of the transport buffer but without Gly-3H-Gln), followed by filtration. The filters were then washed with 5 ml of ice-cold stop solution. The radioactivity associated with filters was counted in a Beckman scintillation spectrometer. Nonspecific binding of the Gly-3H-Gln was determined by adding the transport solution and vesicles directly to the respective ice-cold stop solution, followed by filtering, washing, and counting.

Calculation and Statistics

Kinetic constants of Gly-Gln transport were determined by applying a nonlinear regression method to the Michaelis-Menten kinetic equation using GRAFIT (Sigma): V = (Vmax·[S])/(Km + [S])), where V is Gly-Gln uptake in picomoles per milligram of protein per 45 s, [S] is the external Gly-Gln concentration in millimolar, Vmax is the maximal Gly-Gln uptake, and Km is the concentration of [S] that yielded one-half Vmax. Each rate of Gly-Gln uptake, which was corrected for nonspecific binding, is given as mean ± S.E. of three replicates. Significant differences between values were determined by Student's t test.


RESULTS

Purity of LMV

As shown in Table I, there was no enrichment of either cytochrome c oxidase (mitochondria) or 5'-nucleotidase (plasma membrane). In contrast, there was a more than 100-fold enrichment of a lysosomal membrane enzyme (beta -glucosidase). Furthermore, there was only a modest enrichment of our preparation with a non-membrane-associated lysosomal enzyme (beta -hexosaminidase).

Table I. Activities of marker enzymes

All values represent means ± S.E. of at least three assays. Hexosaminidase and glucosidase are expressed as nmol/min/mg protein. Nucleotidase is expressed as µmol/h/mg protein. Cytochrome c oxidase is expressed as Delta  (log OD)/min/mg protein. All values represent means ± S.E. of at least three assays. Hexosaminidase and glucosidase are expressed as nmol/min/mg protein. Nucleotidase is expressed as µmol/h/mg protein. Cytochrome c oxidase is expressed as Delta  (log OD)/min/mg protein.
Enzyme Homogenate Membrane vesicle

 beta -Hexosaminidase 47  ± 9.50 456  ± 49
Cytochrome c oxidase 1.91  ± 0.29 0.38  ± 0.14
5'-Nucleotidase 2.42  ± 0.09 1.40  ± 0.14
 beta -Glucosidase 1.02  ± 0.07 110  ± 14.2

Establishing Uptake as Transport

Preliminary experiments revealed that there was uptake of Gly-Gln by LMV. To determine whether the observed Gly-Gln uptake by LMV was indeed transport into vesicles, the following experiment was performed. The rates of Gly-Gly uptake were measured as a function of medium osmolarity. Details of this experiment are presented in the legend to Fig. 1. The results showed that the rate of uptake decreased as a linear function of the reciprocal of medium osmolarity. Extrapolation of the data to infinite osmolarity showed no uptake, indicating the Gly-Gln was entirely or mostly transport into an osmotically reactive space. The data also indicate that the vesicles were properly resealed during preparation for uptake studies.


Fig. 1. Gly-Gln uptake as a function of osmolarity. LMV were preloaded with 100 mM sucrose, 100 mM KCl, and 20 mM Hepes/Tris (pH 7.0) and preincubated for 30 min with 50 µM valinomycin. The vesicles were then incubated with the transport buffer containing 0.1 mM Gly-3H-Gln, 100 mM sucrose, 100 mM KCl, 20 mM Mes/Tris (pH 5.0), and 0-700 mM sucrose for 60 min.
[View Larger Version of this Image (11K GIF file)]

Driving Force for Dipeptide Transport

To investigate the driving force for dipeptide transport we determined lysosomal uptake of Gly-Gln in the presence and absence of a sodium or a proton gradient. Details of these experiments are presented in the legend to Fig. 2. As shown in this figure, the imposition of an inwardly directed sodium gradient (Na+ concentrationout = 100, Na+ concentrationin = 0) had no effect, but the imposition of an inwardly directed proton gradient (pHout 5.0/pHin 7.0) transiently stimulated Gly-Gln uptake by LMV. During the initial 2 min of incubation all of the uptake values were significantly (p < 0.01) greater when the outside pH was 5.0 and the inside pH was 7.0 than when both pH values were 7.0. 


Fig. 2. Effect of Na+ and H+ gradients. No gradient (square ): LMV were preloaded with 100 mM KCl, 100 mM sucrose, and 20 mM Hepes/Tris (pH 7.0) and preincubated for 30 min with 50 µM valinomycin. The vesicles were then incubated with a transport buffer containing 0.1 mM Gly-3H-Gln, 100 mM KCl, 100 mM sucrose, and 20 mM Hepes/Tris (pH 7.0). Na+ gradient (diamond ): Conditions were the same as for no gradient, except that the 100 mM KCl in the preloading solution was replaced with 100 mM choline chloride, and 100 mM KCl in the transport buffer was replaced with 100 mM NaCl. H+ gradient (triangle ): Conditions were the same as for no gradient, except the pH of the transport buffer was changed to Mes/Tris (pH 5.0). H+ gradient in the presence of CCCP (open circle : Conditions were the same as in H+ gradient, except that the vesicles were also preincubated with 10 µM CCCP.
[View Larger Version of this Image (12K GIF file)]

To investigate whether the above proton gradient indeed served as the driving force for Gly-Gln transport, the following experiment was performed. Prior to imposition of the proton gradient, the vesicles were preincubated with a proton ionophore (CCCP). As shown in Fig. 2, CCCP did not reduce Gly-Gln uptake by LMV, suggesting that the proton gradient was not the driving force in this case.

To investigate whether membrane potential influences transport of Gly-Gln by the liver LMV, the following experiment was performed. The effect of K+-generated diffusion potential (inside negative) in the presence and absence of an acidic pH (5.0) in the transport medium was determined. The membrane potential was generated by replacing the KCl in the transport medium with 100 mM choline chloride while maintaining the inside concentration of KCl at 100 mM. Results showed that imposition of membrane potential, when the pH of the transport medium was 7.0, transiently stimulated Gly-Gln uptake by the liver LMV (Fig. 3). All of the uptakes during the initial 2 min of incubation were significantly (p < 0.01) greater in the presence than in the absence of membrane potential. The stimulatory effect of membrane potential was greatly enhanced by acidification of the transport medium, resulting in a near 2-fold overshoot in transport of Gly-Gln at 2 min. Therefore, the presence of a membrane potential and an acidic pH was necessary for observing uphill transport of Gly-Gln.


Fig. 3. Effect of membrane potential. LMV were preloaded with 100 mM KCl, 100 mM sucrose, and 20 mM Hepes/Tris (pH 7.0) and preincubated for 30 min with 50 µM valinomycin. No potential (open circle ): The vesicles were then incubated with a transport buffer containing 0.1 mM Gly-3H-Gln, 100 mM KCl, 100 mM sucrose, and 20 mM Hepes/Tris (pH 7.0). With potential (triangle ): The conditions were the same as for no potential, except that the 100 mM KCl in the transport buffer was replaced with 100 mM choline chloride. With potential and acidic pH (square ): Conditions were the same as with potential, except that Hepes/Tris (pH 7.0) in the transport buffer was replaced with Mes/Tris (pH 5.0).
[View Larger Version of this Image (12K GIF file)]

Characterization of Transport

To investigate the affinity and the number of transporters involved in the uptake of Gly-Gln by membrane vesicles we investigated the rate of uptake as a function of dipeptide concentration. The rates of uptake by the liver LMV were determined in the presence of both a membrane potential and an acidic pH. Before this experiment, it was necessary to determine for how long the rate of Gly-Gln transport was linear. The results showed that for at least 50 s the rate was linear (data not shown); therefore, 45 s was chosen as the incubation time for the experiment detailed in the legend to Fig. 4. Eadie-Hofstee plot of data (Fig. 4) showed the presence of a single system for transport of Gly-Gln. The calculation of kinetic constants by the Michaelis-Menten equation showed a low affinity transporter with a Km value of 4.67 ± 0.80 mM and a Vmax value of 880.38 ± 3.81 pmol/mg protein/45 s.


Fig. 4. Gly-Gln uptake as a function of substrate concentration. LMV were preloaded with 100 mM sucrose, 100 mM KCl, and 20 mM Hepes/Tris (pH 7.0) and preincubated for 30 min with 50 µM valinomycin. The vesicles were then incubated for 45 s with a transport buffer containing 100 mM sucrose, 100 mM choline chloride, and 20 mM Mes/Tris (pH 5), and Gly-3H-Gln concentration ranging from 0.1 to 15 mM. The inset shows Eadie-Hofstee transformation of the data; V is the rate of Gly-Gln uptake (pmol/mg protein/45 s) and [S] is the concentration of Gly-Gln in the medium (mM).
[View Larger Version of this Image (13K GIF file)]

Relationship between Transport of Gly-Gln and H+

We used the fluorescent dye acridine orange technique to determine whether there is a coupling between proton and Gly-Gln transport. The results are shown in Fig. 5. There was a less than 5% change in the fluorescence when the liver LMV were added to the medium containing no dipeptide. The fluorescence change became appreciably greater (more than 11%) when the medium contained Gly-Gln.


Fig. 5. Effect of Gly-Gln on H+ transport. Using an alpha  scan fluorescence spectrophotometer, the fluorescence of the incubation medium containing either no (A) or 5 mM (B) Gly-Gln was monitored for 1.5 min before and for 3.5 min after the addition of 40 µl of LMV to the cuvettes. Composition of the incubation medium was as follows: 6 µM acridine orange, 100 mM sucrose, 100 mM KCl, and 20 mM Hepes/Tris (pH 6.5). Before the addition, LMV were preloaded with 100 mM sucrose, 100 mM KCl, and 20 mM Hepes/Tris (pH 7.0). The contents of the cuvettes were continuously stirred during the experiment.
[View Larger Version of this Image (9K GIF file)]

The results of the above experiment suggested that Gly-Gln and H+ are cotransported into the vesicles. To investigate the kinetics of this interaction, we investigated the effect of a range of pH on Gly-Gln transport (Fig. 6). There was a steady decline in the rate of Gly-Gln uptake by the liver LMV when the pH of the transport medium was increased above 5.0 (Fig. 6, right inset). There was a hyperbolic relationship between the rates of Gly-Gln uptake and H+ concentration (Fig. 6). The linearity of the Eadie-Hofstee plot of the data indicated a 1:1 stoichiometry between Gly-Gln and H+ uptake (Fig. 6, left inset). Calculation of the Hill coefficient also showed a coupling ratio of 1 (1.036 ± 0.152). Calculation of kinetic constants by the Michaelis-Menten equation showed a Km of 0.36 ± 0.02 µM (pKa = 6.4) and Vmax of 57.01 ± 1.43 pmol/mg protein/45 s.


Fig. 6. Gly-Gln uptake as a function of H+ concentration. LMV were preloaded with 100 mM KCl, 100 mM sucrose, and 20 mM Hepes/Tris (pH 7.0) and preincubated for 30 min with 50 µM valinomycin. The vesicles were then incubated for 45 s with a transport buffer containing 0.1 mM Gly-3H-Gln, 100 mM choline chloride, and 20 mM Mes/Tris (pH 4.50-6.0) or Hepes/Tris (pH 6.5-7.0). The left inset shows EadieHofstee transformation of the data, where V is the rate of Gly-Gln uptake (pmol/mg protein/45 s) and [H] is the concentration of protons in the incubation medium.
[View Larger Version of this Image (14K GIF file)]

Substrate Specificity of the Transporter

To investigate the substrate specificity of the transporter in the liver LMV, we determined the inhibitory effect of representative groups of amino acids, dipeptides, and tripeptides on Gly-Gln uptake. The results showed (Table II) inhibition by dipeptides and tripeptides but not by amino acids. Due to poor solubility of tetrapeptides at 30 mM concentration, the effect of these oligopeptides on Gly-Gln uptake was not studied.

Table II. Cis inhibition of Gly-Gln uptake

LMV were preloaded with 100 mM sucrose, 100 mM KCl, and 20 mM Hepes/Tris (pH 7.0) and preincubated for 30 min with 50 µM valinomycin. The vesicles were then incubated for 45 s with transport buffer containing 0.1 mM Gly-3H-Gln, 100 mM sucrose, 100 mM choline chloride, 20 mM Mes/Tris (pH 5.0), and 30 mM various test substrates. LMV were preloaded with 100 mM sucrose, 100 mM KCl, and 20 mM Hepes/Tris (pH 7.0) and preincubated for 30 min with 50 µM valinomycin. The vesicles were then incubated for 45 s with transport buffer containing 0.1 mM Gly-3H-Gln, 100 mM sucrose, 100 mM choline chloride, 20 mM Mes/Tris (pH 5.0), and 30 mM various test substrates.
Substrate % uptake

Control (0.1 mM) 100
Gly-Gln 0
Glycine 100
Glutamine 100
Gly-Sar 16
Gly-Pro 0
Gly-Gly-Gly 29
Val-Ala-Leu 0


DISCUSSION

The present study is the first step in the functional characterization of a peptide transporter in the membrane of liver lysosomes. The information obtained reveals that there are functional similarities between this transporter and those located in the brush border membrane of kidney and intestine (16). For example, it is capable of uphill transport, it is stimulated by an acidic pH and membrane potential, its substrates include dipeptides and tripeptides but not amino acids, and it shows a 1:1 stoichiometry between cotransport of Gly-Gln and H+. The uphill transport may have been more pronounced if the membrane orientation of all the vesicles was inside-out. It has been shown (17) that with the current technique of preparation, half of the LMV are oriented inside-out and the other half are oriented outside-out.

The present results suggest that the driving force for uphill transport is membrane potential which normally exists in lysosomes (inside positive/outside negative). At the pH used in the present experiment (4.5-7.0) Gly-Gln is in zwitterionic form. Therefore, its uptake does not add any electrical charge to the transporter. On the other hand, binding of a proton adds a positive charge to the transporter, making it more available for the influence of membrane potential.

The present results may provide an explanation for the disparity among the results of previous studies looking for the presence of an oligopeptide transporter in the liver. Lombardo et al. (18), using functional analysis, did not find any evidence for the presence of a dipeptide transporter in plasma membrane of rat liver. On the other hand, Fei et al. (19), using Northern analysis, found expression of Pept-1 mRNA in the liver. In view of the present data, it is possible that the basis for a positive Northern analysis in the liver (19) is the presence of an oligopeptide transporter in lysosomes. This suggestion is based on reports of a strong homology between genes encoding different oligopeptide transporters (20).

We think that the physiological function of the transporter we have characterized in the lysosomal membrane is mainly to export rather than to import dipeptides because (a) previous studies have shown that the lysosomal carriers can be demonstrated by either uptake or efflux studies (21); (b) as already mentioned, the vesicles have both inside-out as well as outside-out orientations; and (c) it is generally believed that the conditions across lysosomal membranes are the determinant of solute flux. For example, the inside pH is highly acidic, while the outside pH is above neutral. As we have shown in the present study, these conditions greatly favor transport in the direction of cytosol.

The Km of lysosomal oligopeptide transporter (4.67 mM) is considerably greater than the Km of lysosomal amino acid transporters, which ranges between 0.01 and 0.5 mM (6). Usually a greater Km is associated with a greater transport capacity. This may explain the efficiency of dipeptides over amino acids in causing the release of enzymes when lysosomes were incubated with these substrates in vitro (4).

Finally, the present finding leads to a new concept in protein catabolism. Hydrolysis of proteins, whether in the gut lumen, renal tubules, or in liver lysosomes may result in production of considerable amounts of dipeptides (1, 2, 22, 23). However, the hydrolase activity against dipeptides as studied in the intestine (24, 25) is either totally or mostly located in the cell cytoplasm. Furthermore, rates of hydrolysis are much greater when dipeptides are incubated with liver homogenates than with liver lysosomes (26). Therefore, oligopeptide transporters, whether located in the brush border or lysosomal membranes, appear to serve an important physiological function. They provide an active mechanism for transporting dipeptides from a region of low to a region of high dipeptidase activity. In this manner, they participate in completion of the final stage of protein degradation.


FOOTNOTES

*   The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    To whom correspondence should be addressed: University of Pittsburgh Medical Center, Montefiore University Hospital, 200 Lothrop St., Pittsburgh, PA 15213. Tel.: 412-648-6365; Fax: 412-648-6399.
1   The abbreviations used are: CCCP, carbonyl cyanide m-chlorophenylhydrazone; LMV, lysosomal membrane vesicles; Mes, 4-morpholineethanesulfonic acid.

REFERENCES

  1. Coffey, J. W., and de Duve, C. (1968) J. Biol. Chem. 243, 3255-3263 [Abstract/Free Full Text]
  2. Kussendrager, K. D., de Jong, Y., Bouma, J. M. W., and Gruber, M. (1972) Biochim. Biophys. Acta 279, 75-86 [Medline] [Order article via Infotrieve]
  3. Gahl, W. A., Schneider, J. A., and Aula, P. P. (1995) in The Metabolic and Molecular Basis of Inherited Disease (Scriver, C. R., Beaudet, A. L., Sly, W. S., and Valle, D., eds), pp. 3763-3797, McGraw-Hill, New York
  4. Lloyd, J. B. (1971) Biochem. J. 121, 245-248 [Medline] [Order article via Infotrieve]
  5. Bird, S. J., and Lloyd, J. B. (1990) Biochim. Biophys. Acta 1024, 267-270 [Medline] [Order article via Infotrieve]
  6. Forster, S., and Lloyd, J. B. (1988) Biochim. Biophys. Acta 947, 465-491 [Medline] [Order article via Infotrieve]
  7. Goldman, R. (1973) FEBS Lett. 33, 208-212 [CrossRef][Medline] [Order article via Infotrieve]
  8. Bird, S. J., and Lloyd, J. B. (1995) Cell Biochem. Funct. 13, 79-83 [Medline] [Order article via Infotrieve]
  9. Jonas, A. J., and Jobe, H. (1990) Biochem. J. 268, 41-45 [Medline] [Order article via Infotrieve]
  10. Daniel, H., Morse, E. L., and Adibi, S. A. (1991) J. Biol. Chem. 266, 19917-19924 [Abstract/Free Full Text]
  11. Minami, H., Morse, E. L., and Adibi, S. A. (1992) Gastroenterology 103, 3-11 [Medline] [Order article via Infotrieve]
  12. Symons, L. J., and Jonas, A. J. (1987) Anal. Biochem. 164, 382-390 [Medline] [Order article via Infotrieve]
  13. Barrett, A. J. (1972) in Lysosomes, A Laboratory Handbook (Dingle, J. T., ed), pp. 46-126, Elsevier, New York
  14. Hodges, T. K., and Leonard, R. T. (1974) in Methods in Enzymology (Fleischer, S., and Packer, L., eds), Vol. 32, pp. 392-406, Academic Press, New York [Medline] [Order article via Infotrieve]
  15. Prospero, T. D., Burge, M. L. E., Norris, K. A., Hinton, R. H., and Reid, E. (1973) Biochem. J. 132, 449-458 [Medline] [Order article via Infotrieve]
  16. Adibi, S. A. (1996) News Physiol. Sci. 11, 133-137 [Abstract/Free Full Text]
  17. Schneider, D. L. (1983) J. Biol. Chem. 258, 1833-1838 [Abstract/Free Full Text]
  18. Lombardo, Y. B., Morse, E. L., and Adibi, S. A. (1988) J. Biol. Chem. 263, 12920-12926 [Abstract/Free Full Text]
  19. Fei, Y. J., Kanal, Y., Nussberger, S., Ganapathy, V., Leibach, F. H., Romero, M. F., Singh, S. K., Boron, W. F., and Hediger, M. A. (1994) Nature 368, 563-566 [CrossRef][Medline] [Order article via Infotrieve]
  20. Boll, M., Herget, M., Wagener, M., Weber, W. M., Markovich, D., Biber, J., Clauss, W., Murer, H., and Daniel, H. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 284-289 [Abstract/Free Full Text]
  21. Mancini, G. M. S., Beerens, C. E. M. T., and Verheijen, F. W. (1990) J. Biol. Chem. 265, 12380-12387 [Abstract/Free Full Text]
  22. Adibi, S. A., and Mercer, D. W. (1973) J. Clin. Invest. 52, 1586-1594 [Medline] [Order article via Infotrieve]
  23. Stevenson-Stetler, M. A., Flouret, G., and Peterson, D. R. (1981) Am. J. Physiol. 241, F117-F122 [Medline] [Order article via Infotrieve]
  24. Kim, Y. S., Birtwhistle, W., and Kim, Y. W. (1972) J. Clin. Invest. 51, 1419-1430 [Medline] [Order article via Infotrieve]
  25. Nicholson, J. A., and Peters, T. J. (1979) Eur. J. Clin. Invest. 9, 349-354 [Medline] [Order article via Infotrieve]
  26. Bouma, J. M. W., Scheper, A., Duursma, A., and Gruber, M. (1976) Biochim. Biophys. Acta 444, 853-862 [Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.